7 analysts indicate that Crescent Biopharma's earnings estimates are being revised down, with 2027 revenue expected to be $3.4 million and a loss per share of $3.54. Revenue over the past 12 months has declined sharply year on year.
First, 7 analysts say that the current consensus for Crescent Biopharma's revenue and earnings has been revised down. As a result, the company's 2027 revenue is expected to be $3.4 million, with a loss per share of $3.54.
Compared with previous estimates, the 2027 outlook has deteriorated significantly from the initial revenue forecast of $4.8 million and the EPS forecast of a $3.06 loss, with revenue expected to decline by 78%.
While revenue growth among peers is expected to be approximately 21% annually, Crescent Biopharma is expected to contract, strengthening the view that it will lag the industry as a whole.
In conclusion, analysts have become more bearish as the forecast loss per share for next year has increased and the revenue forecast has been revised down.
Additional information and concerns related to the downgrade include the company's recent dilution. Readers are also directed to the related links for further analysis.